Merck
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
Monday, April 26, 2021 9:37PM IST (4:07PM GMT)
Darmstadt, Germany:
New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies from vaccines
Independent study from Israel showed MAVENCLAD-treated patients receiving COVID-19 vaccine were able to mount antibody response similar to that of healthy subjects
Updated safety data show MAVENCLAD-treated patients with confirmed or suspected COVID-19 continue to have a disease course similar to the general population
Not intended for UK and U.S. based media